Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521154-42-00

Enrollment

Registered

2026-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Brief summary

Number and percentage of subjects with Treatment Emergent Adverse Events (TEAEs), overall and by severity, seriousness and relationship to Investigational Product (IP), Number and percentage of subjects with Adverse Events of Special Interest (AESIs), Clinically relevant changes from baseline in laboratory assessments and vital signs

Detailed description

From the first dose of anumigilimab through Week 65: • Serum anumigilimab, During the 52-week Maintenance Period: • Annualized rate of Vaso-occlusive crisis (VOC) (medical facility)

Interventions

DRUGAnumigilimab

DRUGSaline 0.9%

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number and percentage of subjects with Treatment Emergent Adverse Events (TEAEs), overall and by severity, seriousness and relationship to Investigational Product (IP), Number and percentage of subjects with Adverse Events of Special Interest (AESIs), Clinically relevant changes from baseline in laboratory assessments and vital signs	—

Secondary

Measure	Time frame
From the first dose of anumigilimab through Week 65: • Serum anumigilimab, During the 52-week Maintenance Period: • Annualized rate of Vaso-occlusive crisis (VOC) (medical facility)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 30, 2026